Rutgers Health Researchers Have Found That A Weekly Injection of Diabetes Medication COLCE PAINFUL DAILY HOMONE HOMONE HOMONE HOMON SHOTS For People A Rare Genetic Form of Lipodystrophy Fat tissue, according to a study in The new england journey of medicine,

CONGENITAL Generalized Lipodystrophy (CGL), which affects only a few Thousand People Worldwide, Results in Severe Metabolic Disease, Diabetes, Insulin Resistance and Reduced Lifecade Expectance. With no fat tissue for proper storage, fat accumulates in organs such as the liver, Leading to extreme insulin resistance and diabetes.

“These PATITES ARE Severely Ill and Face Markedly Reduced Life Expectation Due to Profound Insulin Resistance,” Said Christoph Buettner, Chief of Endocrinology, Metabolism, Robert Wood Johnson Medical School and Senior Author of the Study.

Currently, The Standard Treatment for CGL Involves Daily Injections of Metreleptin, a synthetic version of the hormone laptin, which is naturally produced exclusively by fate tissue. However, Daily Leptin Shots are Both Expensive – Costing Hundreds of Thousands of Dollars Annually –and Particularly Painful for Cgl Patients.

“When you get yourself with, for example, insulin, you inject into subcutaneous fat, but these patients do’t havhe,” Said svetlana ten, associate professor of pediatry of pediatry. “Each injection is painful.”

In a recent study, resarchers explred if the diabetes and obesity drug tirzepatide (the active ingredient in zepbound and mounjaro) Cold Improve Cgl, ASTISULIN RESTANCE. Tirzepatide is administerred through a weekly injection, potentially reviewing the burden and pain associated with cgl treatment. It is also much more affordable than metreleptin.

The first patient, a 23-yar-old man who has refused the penfull daily treatment with laptin and insulin for two years, Saw his average blood glucose DRP from 252 to 128 Milligrams Per Dress on the maximum dose of tirzepatide.

His Blood Glucose, which hasn at healthy levels between 70 and 140 milligrams per deciliter in 8% of readings, remained at healthy levels in 93% of readings, an almost normalization white ect insulin.

The Second Patent, A 64-ELD WOMAN WHORED Supplemental Injections Alone.

“The Surprise Here was that when we Stopped Leptin and Gave Tirzepatide, The Patient was very well controlled, probally batter than whose brele she was taken leptin,” Buettner Said.

“Leptin is an important hormone, made only by fat tissue, that is an important regulator of metabolism, so liptin therapy made intuitive senses in patints with cgl. Zepatide, is not made in adipose tissue, and While tirzepatide is an insulin sensitizer, we did not expect it would have thought such potency in patients with cgl. “

While Both Tirzepatide and Leptin work in the brain, they do so through differentialing pathways, acting on different neurons in distinct brain regions. This sugges that Leptin and GLP1 Signaling May have more extended overlap than so far suggested.

The Researchers Plan a Larger Trial to Validate these Initial Results, Thought Recruiting Enough Patients will be challenging giving giving the condition’s Rarity.

If the results hold up in larger studies, tirzepatide un offer cgl patients an easy and potentially more affordable treatment option. However, Buettner said more research is needed to evaluate bot the long-term efficacy and safety in this specific patient population and beyond that in other leptin-deciants.